lifestyle.chroniccities.us

Author: Cloudbreak Pharma, Inc.

Cloudbreak Pharma Announces Presentation on its Multi-Kinase Inhibition (MKI) Platform and Ongoing Clinical Programs at Eyecelerator @ ARVO 2026

April 22, 2026
Cloudbreak Pharma Announces Launch of Cloudbreakpharma.com to Raise Awareness of its Pipeline of Novel First-in-Class Therapeutics to Treat Serious Underserved Ophthalmic Diseases

April 9, 2026
Cloudbreak Pharma Announces Successful End-of-Phase-2 Meeting and Alignment with FDA on Phase 3 Path Forward for CBT-004

January 27, 2026